The quest for the Grail is beset with challenges.
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Discount pricing and poor first day defies the recent trend for floating device makers.
In terms of private investments, 2020 was the year of the liquid biopsy.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.